149 related articles for article (PubMed ID: 18161868)
21. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
[TBL] [Abstract][Full Text] [Related]
22. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
23. [Changes in bone micro-architecture and bone mineral density following experimental osteonecrosis of femoral head by local injection of ethanol in canines].
Li H; Zhang C; Zeng B
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2008 Mar; 22(3):281-9. PubMed ID: 18396703
[TBL] [Abstract][Full Text] [Related]
24. Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis.
Hatoum HT; Lin SJ; Smith MR; Guo A; Lipton A
Clin Breast Cancer; 2011 Jun; 11(3):177-83. PubMed ID: 21665138
[TBL] [Abstract][Full Text] [Related]
25. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
[TBL] [Abstract][Full Text] [Related]
26. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.
Le Gall C; Bellahcène A; Bonnelye E; Gasser JA; Castronovo V; Green J; Zimmermann J; Clézardin P
Cancer Res; 2007 Oct; 67(20):9894-902. PubMed ID: 17942921
[TBL] [Abstract][Full Text] [Related]
27. Stimulation of bone formation by zoledronic acid in particle-induced osteolysis.
Wedemeyer C; von Knoch F; Pingsmann A; Hilken G; Sprecher C; Saxler G; Henschke F; Löer F; von Knoch M
Biomaterials; 2005 Jun; 26(17):3719-25. PubMed ID: 15621262
[TBL] [Abstract][Full Text] [Related]
28. Zoledronic acid improves femoral head sphericity in a rat model of perthes disease.
Little DG; McDonald M; Sharpe IT; Peat R; Williams P; McEvoy T
J Orthop Res; 2005 Jul; 23(4):862-8. PubMed ID: 16023001
[TBL] [Abstract][Full Text] [Related]
29. Lignan-rich sesame seed negates the tumor-inhibitory effect of tamoxifen but maintains bone health in a postmenopausal athymic mouse model with estrogen-responsive breast tumors.
Sacco SM; Chen J; Power KA; Ward WE; Thompson LU
Menopause; 2008; 15(1):171-9. PubMed ID: 17545920
[TBL] [Abstract][Full Text] [Related]
30. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
Luo KW; Ko CH; Yue GG; Gao S; Lee JK; Li G; Fung KP; Leung PC; Evdokiou A; Lau CB
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1025-36. PubMed ID: 25431338
[TBL] [Abstract][Full Text] [Related]
31. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
Bhoopalam N; Campbell SC; Moritz T; Broderick WR; Iyer P; Arcenas AG; Van Veldhuizen PJ; Friedman N; Reda D; Warren S; Garewal H
J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
[TBL] [Abstract][Full Text] [Related]
32. Effect of combined treatment with zoledronic acid and parathyroid hormone on mouse bone callus structure and composition.
Casanova M; Herelle J; Thomas M; Softley R; Schindeler A; Little D; Schneider P; Müller R
Bone; 2016 Nov; 92():70-78. PubMed ID: 27542660
[TBL] [Abstract][Full Text] [Related]
33. Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.
Tanaka M; Mori H; Kayasuga R; Ochi Y; Kawada N; Yamada H; Kishikawa K
Bone; 2008 Nov; 43(5):894-900. PubMed ID: 18687415
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of osteoclasts does not prevent joint ankylosis in a mouse model of spondyloarthritis.
Lories RJ; Derese I; Luyten FP
Rheumatology (Oxford); 2008 May; 47(5):605-8. PubMed ID: 18334523
[TBL] [Abstract][Full Text] [Related]
35. Anti-tumor and anti-osteolysis effects of the metronomic use of zoledronic acid in primary and metastatic breast cancer mouse models.
Luo KW; Ko CH; Yue GG; Lee MY; Siu WS; Lee JK; Shum WT; Fung KP; Leung PC; Li G; Evdokiou A; Lau CB
Cancer Lett; 2013 Oct; 339(1):42-8. PubMed ID: 23896464
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of zoledronic acid rapid infusion in lung cancer patients with bone metastases: a single institution experience.
Kotteas E; Alamara C; Kiagia M; Pantazopoulos K; Boufas A; Provata A; Charpidou A; Syrigos KN
Anticancer Res; 2008; 28(1B):529-33. PubMed ID: 18383897
[TBL] [Abstract][Full Text] [Related]
37. Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients.
Chae YS; Kim JG; Moon JH; Kim SN; Lee SJ; Kim YJ; Sohn SK
Bone Marrow Transplant; 2009 Jul; 44(1):35-41. PubMed ID: 19139732
[TBL] [Abstract][Full Text] [Related]
38. Novel cytosine deaminase fusion gene enhances the effect of radiation on breast cancer in bone by reducing tumor burden, osteolysis, and skeletal fracture.
Goblirsch M; Zwolak P; Ramnaraine ML; Pan W; Lynch C; Alaei P; Clohisy DR
Clin Cancer Res; 2006 May; 12(10):3168-76. PubMed ID: 16707617
[TBL] [Abstract][Full Text] [Related]
39. Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats.
Uyar Y; Baytur Y; Inceboz U; Demir BC; Gumuser G; Ozbilgin K
Maturitas; 2009 Jul; 63(3):261-7. PubMed ID: 19386450
[TBL] [Abstract][Full Text] [Related]
40. A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy.
Miwa S; Mizokami A; Konaka H; Izumi K; Nohara T; Namiki M
Jpn J Clin Oncol; 2009 Nov; 39(11):745-50. PubMed ID: 19808839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
